Phaseline

Companies › PolarityTE

PolarityTE: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Metabolic and endocrine.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SkinTE
Autologous heterogeneous skin construct derived from patient's own full-thickness skin
–Phase 3Diabetic Foot–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06140303SkinTEPhase 3Diabetic FootMetabolic and endocrineJan 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Royal Biologics HealthTech Wound Care Ascendis Pharma Bone Diseases BioXTek Blue Blood Biotech

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.